Previous
Previous

The use of a patient-centric neuronal cell model of Beta-Propeller Protein-Associated Neurodegeneration (BPAN) as a platform to develop novel therapies

Next
Next

Biomarker correlates of neurocognitive outcomes in the cerebrospinal fluid in MPS I